Search results
Zacks Industry Outlook Highlights Dyne Therapeutics, Silence Therapeutics, Alaunos Therapeutics,...
Zacks via Yahoo Finance· 1 year agoFor Immediate Release Chicago, IL – January 19, 2023 – Today, Zacks Equity Research discusses Dyne...
Zacks Industry Outlook Highlights Alkermes, Geron, Immunocore and BELLUS Health
Zacks via Yahoo Finance· 2 years agoFor Immediate Release Chicago, IL – June 13, 2022 – Today, Zacks Equity Research discusses Alkermes...
Zacks Industry Outlook Highlights Sarepta, Exelixis, Immunocore, Editas and Puma Biotechnology
Zacks via Yahoo Finance· 3 months agoFor Immediate Release Chicago, IL – February 14, 2024 – Today, Zacks Equity Research discusses...
Immunocore Holdings PLC Reports Q1 2024 Earnings: Misses EPS Estimates, Surpasses Revenue Forecasts
GuruFocus.com via Yahoo Finance· 3 hours agoRevenue: Reported $70.3 million in Q1 2024, up 36% from $51.6 million in Q1 2023, falling short of...
Alaunos Therapeutics, Inc. (NASDAQ:TCRT) Q4 2022 Earnings Call Transcript
Insider Monkey via Yahoo Finance· 1 year agoAlaunos Therapeutics, Inc. (NASDAQ:TCRT) Q4 2022 Earnings Call Transcript March 7, 2023 Operator:...
Alaunos (TCRT) to Wind Down Sole Clinical Study, Stock Dips 65%
Zacks via Yahoo Finance· 9 months agoDue to a lack of funding needs, Alaunos (TCRT) decides to end its only clinical study. The company...
Alaunos (TCRT) to Report Q4 Earnings: What's in the Cards?
Zacks via Yahoo Finance· 1 year agoAlaunos Therapeutics (TCRT) is expected to provide an update on its pipeline candidates, Library...
AstraZeneca (AZN) Boosts Cell Therapies With Neogene Deal
Zacks via Yahoo Finance· 1 year agoAstraZeneca AZN announced an agreement to acquire private biotech, Neogene Therapeutics to build its...
Moderna (MRNA), Immatics Ink Deal to Develop New Cancer Therapies
Zacks via Yahoo Finance· 8 months agoModerna MRNA has entered into a strategic research and development collaboration with Immatics IMTX...
Adaptimmune (ADAP) Up 7%, Gets T-Cell Programs Rights From GSK
Zacks via Yahoo Finance· 1 year agoAdaptimmune Therapeutics (ADAP) enters into a transition deal with GSK to regain rights to its...